Latticon

Latticon Antibody Therapeutics, Inc. (LAT), established in March 2021, is a science-driven biotechnology company dedicated to advancing the discovery and global development of world-class biotherapies for the treatment of cancer, cardiovascular and autoimmune diseases. 

Latticon Antibody Therapeutics, Inc. (LAT), established in March 2021, is a science-driven biotechnology company dedicated to advancing the discovery and global development of world-class biotherapies for the treatment of cancer, cardiovascular and autoimmune diseases. Our overarching mission revolves around harnessing innovative concepts and cutting-edge technologies to develop novel antibody-based therapeutics which will improve disease burdens and the quality of life for patients with significant unmet medical needs.

LAT is a wholly-owned subsidiary of Latticon Biopharmaceuticals (LB). The goal of LB and LAT is to establish pioneering research and development projects, including the discovery, design, and preclinical development of biotherapies, to address highly unmet medical needs.

LAT is located in Gaithersburg, Montgomery County, Maryland, a biotechnology and life sciences center with more than 300 biotechnology companies, such as AstraZeneca and GlaxoSmithKline, major biomedical research institutions, including Johns Hopkins University and the Howard Hughes Medical Institute (HHMI), and federal government agencies, including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). The company's long-term goal is to establish a leading position in the development of innovative biotherapies and benefit patients worldwide.